KalVista Pharmaceuticals, Inc. (KALV)

20.48 +0.92 (+4.70%) USD  |  NASDAQ  |  Apr 17, 16:00
20.48 0.00 (0.00%) After-Hours: 05:13
More

KalVista Pharmaceuticals SG&A Expense (Quarterly) : 61.00M for Dec. 31, 2025

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for KALV.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Intellia Therapeutics, Inc. 33.08M
Recursion Pharmaceuticals, Inc. 33.66M
Tango Therapeutics, Inc. 9.763M
Modular Medical, Inc. 1.839M
Iovance Biotherapeutics, Inc. 36.40M